Could swapping out red blood cells help treat a rare seizure disorder?
NCT ID NCT04137692
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This study tests whether replacing a patient's own red blood cells with healthy donor cells can improve brain function in people with GLUT1 deficiency syndrome, a rare genetic condition that causes seizures and movement problems. The approach aims to boost glucose delivery to the brain by using donor cells that have normal glucose transporters. The trial plans to enroll 12 people aged 16 to 80 who have not been helped by the standard ketogenic diet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUCOSE TRANSPORTER TYPE 1 DEFICIENCY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
red blood cell exchange transfusion
What this could lead to
If it works, this could point toward a new way to treat GLUT1 deficiency by improving glucose delivery to the brain, potentially reducing seizures and movement problems.
What could go wrong
This is a very early, small trial (12 people) that is currently suspended. The treatment is complex and carries risks like transfusion reactions or infection. It may not improve symptoms or could cause harm.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.